Cue Biopharma, Inc.
- Last sale
- Nov 12, 2026 · -5.61%
- Market cap
- $137.01M
- 7.75M shares
- Filings
- 558
Q3 2026+195.7% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026+20.8% FY25 yoy
- $137.01M
- —
- 3.8×
- 3.6×
- -37.39%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $27,466,000 | reported | |
| FY 2024 | 2024-12-31 | $9,287,000 | reported | |
| FY 2023 | 2023-12-31 | $5,490,000 | reported | |
| FY 2022 | 2022-12-31 | $1,245,000 | reported | |
| FY 2021 | 2021-12-31 | $14,941,370 | reported | |
| FY 2020 | 2020-12-31 | $3,154,325 | reported | |
| FY 2019 | 2019-12-31 | $3,458,331 | reported | |
| FY 2018 | 2018-12-31 | $1,142,604 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2023 | — | $0.00 | $0.00 | — | 48.64M sh | +12.7% | — |
| FY2022 | — | $200.00K | $200.00K | — | 43.17M sh | +30.8% | — |
| FY2021 | — | $750.13K | $750.13K | — | 33.01M sh | +8.4% | — |
| FY2020 | — | $271.05K | $271.05K | — | 30.46M sh | +14.6% | — |
| FY2019 | — | $91.03K | $91.03K | — | 26.58M sh | +28.2% | — |
Pharmaceutical preparations
Cue Biopharma, Inc. is the 147th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
BHSTBioharvest Sciences Inc.$34.5M37.0%32.3%$39.7MZOMDFZomedica Corp.$32.0M17.4%255.6%$78.4MVSTMVerastem, Inc.$30.9M209.1%677.6%$1.1BFHTXFoghorn Therapeutics Inc.$30.9M36.8%240.3%$123.5M
CUECue Biopharma, Inc. (this company)$27.5M195.7%96.9%$128.4M
CELUCelularity Inc$26.6M51.0%345.4%$21.8MTRDAEntrada Therapeutics, Inc.$25.4M87.9%565.5%$203.2MALMSAlumis Inc.$24.1M—1,011.7%$796.5MNAMSNewAmsterdam Pharma Co N.V.$22.5M50.6%905.7%$2.4BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Cue Biopharma, Inc. · CIK 1645460 · Engraved from SEC EDGAR